Renal

Localized

T1b or greater (has not spread beyond the kidney)

IRB#16576
Atezolizumab vs placebo as adjuvant therapy following nephrectomy

IRB#18121
Nivolumab Combined with Cabozantinib versus Sunitinib

IRB#17027
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology

No trials Currently Available

Clear Cell

No Prior Systemic Therapy

Matastectomy Candidate

IRB#17027
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology

No trials Currently Available

Cytoreductive Nephrectomy Candidate

Prior Systemic Therapy

Non-Clear Cell

No Trials Currently Available

Metastatic/advanced

IRB#16085
S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib

Key

Open for Enrollment
In Development
Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php